Cavendish reiterate 40p target3 Jun 2024 10:52
Cavendish this morning retain their 40p target price, and summarise (extracts) FYI:
"HVO have announced a new contract win to undertake an Omicron characterisation study with a mid-sized pharmaceutical company, worth £2.5m and expected to start in Q4 2024, but with the majority of the revenue recognised in FY2025E. The study will be run out of the new Canary Wharf (CW) facility. Although relatively small in the context of HVO’s total revenue base, it gives a little more clarity on FY2025E revenues, which the company has already characterised as having “good visibility” prior to this announcement. Moreover, we see this as evidence that global concerns over C19 have not gone away, with pharmaceutical companies still working on novel vaccines and anti-viral agents for Omicron and other respiratory pathogens."
"As per the FY2023A results release, HVO already has 90% of its £62m FY2024E revenue guidance contracted, with good visibility in to 2025, which this contract will enhance. - It is notable that a number of global vaccine manufacturers, including GSK, Pfizer, Moderna, BioNTech and CureVac, have seen significant share price appreciation recently, likely related to mounting concerns over the emergence of human cases of bird flu (H5N1) in the US. - HVO is strongly positioned for future growth.
HVO operates in the structurally attractive, fastgrowing HCT industry. It is a world leader, with unique benefits versus its competitors, and as such is in demand among pharma companies. 2024 targets point to another year of strong revenue and profit growth, with a history of over-delivery. Longer-term targets have been set, which we believe are achievable, and offer double-digit compound revenue, profit and cash flow growth, while the company has established a progressive dividend policy after the special paid in 2023."